Cellectar Biosciences Presents Efficacy Data for Iopofosine I 131 in Relapsed/Refractory Waldenström Macroglobulinemia

Cellectar Biosciences presented compelling efficacy data from a Phase 2b clinical trial of iopofosine I 131 in patients with relapsed or refractory Waldenström macroglobulinemia, particularly those previously treated with BTK inhibitors. A subgroup achieved an 87.5% overall response rate and a 79.2% major response rate.